Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT), http://www.pvct.com,
a development-stage oncology and dermatology biopharmaceutical company,
announced that it has appointed Dr. Joseph M. Chalil, MD, MBA, FACHE, to
its Strategic Advisory Board.
Dr. Chalil is Associate Director, Health Science Executives of
Boehringer Ingelheim, the world’s largest privately held pharmaceutical
company. Headquartered in Ingelheim, Germany, the company operates
globally in more than 50 countries. In 2012, Boehringer Ingelheim
achieved net sales of 19.1 billion (USD); R&D expenditure in the
business area of prescription medicines reached a quarter of its net
sales.
In addition to his responsibilities at Boehringer Ingelheim, Dr. Chalil
is the Co-Chair for the Industry Physician Committee of the American
Association of Physicians of Indian Origin (AAPI) and has served as
Scientific Advisor to AAPI for the past three years. AAPI is the second
largest physician organization in the US second only to AMA, and the
largest ethnic medical organization in the country.
A veteran of the United States Navy Medical Corps, Dr. Chalil is also
board certified in healthcare management, and has been awarded
Fellowship by the American College of Healthcare Executives, an
international professional society of more than 40,000 healthcare
executives who lead hospitals, healthcare systems and other healthcare
organizations.
Dr. Chalil is an expert in US Healthcare policy and a strong advocate
for patient centered care, and has also served as an advisor to various
national political campaigns on healthcare issues.
As the former CEO of Clinical Consultants International, he represented
prominent healthcare companies, including GE Healthcare, Genpact, HIRCO
Group, Godrej Ltd, KLE University, Somaiya Group, Pushpanjali Crosslay
Hospital, Excel Life Sciences and various international pharmaceutical
firms over the past decade.
Dr. Chalil completed his higher studies in University of Medicine and
Dentistry of New Jersey, Davenport University, JJM Medical College and
Baylor College of Medicine. He has been a Visiting Professor at various
Universities and serves on various company Boards.
Craig Dees, Ph.D., CEO of Provectus Pharmaceuticals said, “Adding Dr.
Chalil to our Strategic Advisory Board will strengthen our collective
expertise in healthcare marketing, sales and business development. His
depth and breadth of experience in these fields will enable Provectus to
take greater advantage of the opportunities that lie ahead.”
Dr. Chalil said, “I am honored to join the Provectus Strategic Advisory
Board at this critical juncture of the company’s development as it
brings PV-10 and other treatments through the developmental regulatory
approval processes.”
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology and
dermatology therapies. Its novel oncology drug PV-10 is designed to
selectively target and destroy cancer cells without harming surrounding
healthy tissue, significantly reducing potential for systemic side
effects. Its oncology focus is on melanoma, breast cancer and cancers of
the liver. The Company has received orphan drug designations from the
FDA for its melanoma and hepatocellular carcinoma indications. Its
dermatological drug PH-10 also targets abnormal or diseased cells, with
the current focus on psoriasis and atopic dermatitis. Provectus has
recently completed Phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis and
psoriasis. Information about these and the Company's other clinical
trials can be found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus please visit the Company's
website at www.pvct.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained
herein are subject to certain risks and uncertainties that could cause
actual results to differ materially from those reflected in the
forward-looking statements. Readers are cautioned not to place undue
reliance on these forward-looking statements, which reflect management's
analysis only as of the date hereof. The company undertakes no
obligation to publicly revise these forward-looking statements to
reflect events or circumstances that arise after the date thereof.
MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50819566&lang=en
Copyright Business Wire 2014